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A B S T R A C T
Biosensors are rising technologies in the pharmaceutical field for medicine discovery, development and Quality
Control (QC) stages. Surface acoustic wave (SAW) biosensor employs acoustic waves generated by oscillating a
piezoelectric crystal quartz plate to meas. mass and viscosity, and allows to detect and quantify binding events
between the analyte and an immobilized interacting ligand. We present here a SAW biosensor based approach
for the functional quantification of Escherichia coli L-asparaginase (E. coli L-ASNase), using polyclonal antibody
(pAb) as the interaction partner immobilized on the chip. Different immobilization strategies of pAb were in-
itially evaluated, resulting in the BS3 activated amide coupling via protein G strategy as the final immobilization
method. The method was validated by evaluating the selectivity, linearity, as well as accuracy (a recovery of
102.4%) and precision (RSD of 8.5%). The application of the validated method on different samples encom-
passing different lots of E. coli L-ASNase, deamidated E. coli L-ASNase and dry-heated E. coli L-ASNase (80 °C,
10min) indicated the suitability of the developed SAW method to quantify E. coli L-ASNase. We suggest this SAW
method can be adopted as a pharmaceutical QC method.
1. Introduction
L-asparaginase (L-ASNase) is a tetrameric enzyme, and has been a
universal component of therapy for pediatric acute lymphoblastic leu-
kaemia (ALL) since 1970's [1]. The clinically used L-ASNase prepara-
tions are derived from Escherichia coli (E. coli) or from Erwinia chry-
santhemi [1], with a tetrameric molecular weight (MW) of 136 320 Da
resp. 140 320 Da [2,3]. The mechanism of anti-ALL activity of L-ASNase
is that leukemic cells cannot synthesize themselves sufficient L-aspar-
agine (L-Asn) required for their protein synthesis; leukemic cells
therefore have to depend upon the external L-Asn supply from the
plasma and tissues [4]. The administration of L-ASNase quenches the
external source of L-Asn, hence starving cancer cells [4]. For the
treatment of pediatric ALL, remission induction therapy including L-
ASNase, vincristine, corticosteroid and anthracycline has been the
mainstay of the initial stage of the treatment [5]. In the consolidation
phase of treatment, L-ASNase is also adopted in the therapy together
with methotrexate, 6-mercaptopurine, vincristine and/or prednisone
[5]. Three forms of L-ASNase are currently used in clinical practice,
namely: (native) E. coli L-ASNase, PEGylated E. coli L-ASNase, and Er-
winia L-ASNase [5]. Among these forms, E. coli L-ASNases are used for
first-line treatment of ALL, whereas Erwinia L-ASNase is used as second
or third line treatment [6]. In this study, E. coli L-ASNase was in-
vestigated by a biosensor based functional quantification method, with
an anti- E. coli L-ASNase antibody used as the analytical interaction
partner.
Acoustic wave biosensors is a nanogram sensitive technology, em-
ploying acoustic waves generated by oscillating a piezoelectric crystal
quartz plate to meas. mass and viscosity changes [7]. Acoustic wave
biosensors can be classified into surface acoustic wave (SAW), bulk
acoustic wave, and acoustic plate mode devices depending on the
acoustic wave guiding process [8]. A surface acoustic wave is a me-
chanical acoustic wave that propagates to a confined area of a piezo-
electric crystal [9]. Love wave SAW sensor is a recent developed device
developed for integration in lab-on-a-chip systems. Love waves propa-
gate near the surface of the piezoelectric material, the velocity and the
amplitude of the wave depend on the changes occurring in the media
near the surface [9]. The SAW biosensor proved to be a sensitive and
effective technology for label-free detection of molecular interactions.
Binding reactions are detected by measuring changes in surface wave
velocity mainly caused by mass adsorption or viscosity changes on the
surface layer [10]. Using SAW instruments as biosensors, antibodies or
receptors are immobilized on the sensing layer to bind with analytes,
using a hydrogel layer on the sensor surface [11]. To date, a wide range
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of analytes have been studied by SAW, involving proteins, DNA, large
cells and bacteria [12–17], mostly from a diagnostic and therapeutic
perspective [15,18,19].
Up till now, only a few biosensor approaches have recently been
reported, using L-ASNase as immobilized ligand for the determination
of other analytes [20–22]. A surface plasmon resonance (SPR) method
for the rapid detection of anti-ASNase antibodies was developed, using
L-ASNase as the binding target immobilized on the chip surface [21]. In
another study, one microplate-based biosensor was used for the de-
termination of the L-asparagine in biological samples, with the L-ASNase
immobilized on the microplate, based on the colorimetric meas. ment of
ammonia formation using the Nessler's reagent [22]. Until now, no
SAW or other biosensor method has been reported for the determina-
tion of L-ASNase itself. In this study, we developed a SAW biosensor
based functional quantification method for E. coli L-ASNase. The pAb of
E. coli L-ASNase was immobilized on the chip, with E. coli L-ASNase as
the running analyte. After an initial immobilization investigation, the
method was validated and applied on different E. coli L-ASNase samples.
2. Materials and methods
2.1. Materials and equipment
Chemicals were purchased from Sigma-Aldrich (Diegem, Belgium)
and Merck (Overijse, Belgium). Paronal® samples, i.e. E. coli L-ASNase
preparation without excipients (label claim of 10’000 IU per vial;
Kyowa Hakko Kiri Co., Ltd.) (Tokyo, Japan), were obtained from
Takeda Pharmaceutical Co., Ltd. (Brussels, Belgium). The polyclonal
rabbit antibodies (isotype IgG) against E. coli L-ASNase were purchased
from Antibody-online GmbH (Aachen, Germany). ERWINASE®, i.e.
Erwinia chrysanthemi L-ASNase preparation was obtained from EUSA
Pharma (Hertfordshire, England). SAW experiments were performed
with the five channel SAM®5 Blue from SAW Instruments GmbH (Bonn,
Germany; now: NanoTemper Technologies (Munich, Germany)).
Unmodified sensor chips (i.e. gold layered) were also purchased from
SAW Instruments GmbH. PD-10 desalting-column (column I.D. 15mm,
particle size 85–260 μm) was obtained from GE Healthcare (Machelen,
Belgium). All SAW experiments were performed at 20 °C using HBS
running buffer (10mM HEPES, pH 7.4 with 150mM NaCl), with a flow
rate of 30 μl/min.
2.2. Preparation of a carboxymethylated dextran hydrogel chip
(Supplementary Information 1 for reaction schemes)
The plain gold chips were initially pre-cleaned by a 3min ultra-
sonification in deionized water, followed by 3min in aceton and 3min
in isopropanol. The surface was dried under N2 stream. A chemical
etching proced. was subsequently performed by immersing the chip for
3min in a freshly prepared boiling solution of 5:1:1 water, ammonia
and hydrogen peroxide at 70 °C, to remove all organic residues from the
gold layer.
Afterwards, the chip was rinsed in water and dried under N2 stream
[23–25]. Carboxymethylated (CM-) dextran hydrogel chip was prepared
following existing proced.s [17]. Briefly, the sensor chip was incubated
in a 2mM 11-mercapto-1-undecanol (MUD) solution in ethanol over-
night to form a self-assembled monolayer with end-standing hydroxyl
groups. Next, the MUD modified chip was sonicated three times for 2min
in 100% ethanol. Activation of the hydroxyl groups was achieved with
0.6M epichlorohydrin in a 1:1 mixt. of diglyme and 0.4M NaOH solu-
tion. After the incubation of 4 h, the chip was covered with a 0.3 g/ml
dextran in 0.1M NaOH. Finally the dextran hydrogel was carboxylated
by covering the chip in a 1M bromoacetic acid solution in 2M NaOH for
at least 20 h. The chip was rinsed with water and N2-dried. The chip was
stored at 4 °C in N2 environment to prevent microbial growth and che-
mical degradation. The CM-dextran hydrogel chips were used within one
month after their preparation.
2.3. Method development (Supplementary Information 2 for reaction
schemes)
2.3.1. The immobilization of the pAb
10 μl of 0.1% SDS was first injected to clean up all non-specifically
bound molecules on the chip, followed by equilibration with HBS
running buffer for 20min.
2.3.1.1. Immobilization of pAb via amine coupling. The pAb was
immobilized according to Ref. [26]: the chip was activated by
injection of 130 μl of a 200mM N-(3-dimethylaminopropyl)-N′-
ethylcarbodiimide hydrochloride (EDC) and 50mM N-
hydroxysuccinimide (NHS) mixt. at a flow rate of 12.5 μl/min. Three
successive injections of 25 μg/ml pAb in 10mM sodium acetate buffer
pH 4.5 were carried out for 670 s to obtain an effective immobilization
of the pAb. Finally, 130 μl of 1M ethanolamine (pH 8.5) was injected to
block the remaining active sites.
2.3.1.2. Immobilization of pAb via thiol coupling. The pAb was first
modified with SPDP as follows: an aliquot of 2.5mM succinimidyl 3-
(2-pyridyldithio)propionate (SPDP) in ethanol was added to a solution
of 2.5mg/ml of antibody in 0.1M phosphate buffer 0.1M NaCl, pH 7.5,
with protein molar ratio of approximately 10 [27]. The mixt. was
allowed to react for 1 h at room temperat. and at low agitation. 2.5ml
of above mixt. was transferred to the PD-10 desalting-column; the
reaction was stopped by desalting the mixt. using 0.15M NaCl as the
elution buffer. Thiolated antibodies were then prepared by reduction of
the SPDP-modified pAb (50 μg/ml) with 50mM DTT in 50mM borate
buffer, pH 8.5. The mixt. was allowed to react 30min at room temperat.
maintaining a low agitation. The reaction was stopped by PD-10
desalting-column treatment. After activation of the sensor chip with
1:1 EDC:NHS, 20 μl of 80mM 2-(2-pyridinyldithio) ethaneamine
hydrochloride (PDEA, thiol reagent) solution in 0.1M sodium
formate, pH 4.3, were injected. Afterwards, multiple 140 μl injections
of the thiolated pAb were performed in order to achieve an efficient
immobilization. Finally, 130 μl of 1M ethanolamine, pH 8.5, was
injected to block the remaining active sites. Deactivation of excess
reactive disulphides was performed by 20 μl injection of 50mM L-
cysteine in 0.1M formate buffer containing 1M NaCl, pH 4.3.
2.3.1.3. EDC-mediated carboxyl coupling. For carboxyl coupling by EDC
mediation, the antibody was modified according to the following
proced [28]. 6 μM of EDC in 0.1M 4-morpholinoethanesulfonic acid
(MES) buffer pH 4.5 was added to 0.1mg/ml pAb solution, the mixt.
reacts for 2 h in room temperat. The chip was activated by 130 μl 1:1
NHS:EDC injection and modified with hydrazide by 140 μl injection
(30 μl/min) of 5mM carbohydrazide in water. Multiple 140 μl
injections of the EDC-modified pAb were performed, then the
remaining active esters were inactivated by 130 μl 1M ethanolamine
(pH 8.5) injection. Finally, 0.1 M sodium borohydride in 0.1M sodium
acetate buffer (pH 4.0) was injected for 20min to stabilize the
antibody-modified surface.
2.3.1.4. Immobilization of pAb via aldehyde coupling. For aldehyde
immobilization, antibodies were firstly oxidized [27,29]. 2 ml of
50mM sodium metaperiodate in 0.1M acetate buffer pH 5.5 was
added to 2ml of 1mg/ml pAb solution in the same buffer, the mixt.
was allowed to react for 20min in ice. The reaction was stopped by
desalting the mixt. on a PD-10 desalting-column with 10mM sodium
acetate buffer (pH 4.0) as the eluent. The chip was activated by 130 μl
1:1 NHS:EDC injection and modified with hydrazide by 140 μl injection
of 5mM carbohydrazide in water. Multiple 140 μl injections of the
oxidized-antibody were performed using sodium acetate pH 4.5 as
running buffer. Any remaining active esters were inactivated by 130 μl
1M ethanolamine (pH 8.5) injection. Finally, 0.1M sodium
borohydride in 0.1M sodium acetate buffer (pH 4.0) was injected for
H. Yao, et al. Talanta 203 (2019) 9–15
10
20min to stabilize the antibody-modified surface.
2.3.1.5. Immobilization of pAb via protein G. For protein G capturing,
50 μg/ml protein G (in 10mM sodium acetate buffer pH 4.5) was
covalently immobilized to the surface via amine coupling using three
130 μl injections. After deactivation of the remaining active esters by
the injection of 130 μl of 1M ethanolamine (pH 8.5), the pAb was
coupled to the protein G by three 140 μl injections of 25 μg/ml pAb in
HBS buffer (pH 7.4) [30,31].
2.3.1.6. BS3 activated amide coupling via protein G. 50 μg/ml protein G
(in 10mM sodium acetate buffer pH 4.5) was covalently immobilized to
the surface using amine coupling by performing three 130 μl injections.
After the deactivation of the remaining active esters, antibody
immobilization was performed by three successive 140 μL injections
of 25 μg/ml antibody in acetate buffer, pH 4.5. Then, the 10 μL of 1mM
of the crosslinker bis [sulfosuccinimidyl] suberate (BS3) was injected by
30 μL/min 100mM Gly-HCl solution (pH 2.7) was injected, in order to
quench the crosslinking reaction and remove unreacted molecules
[30,31].
2.3.2. Feasibility evaluation of SAW binding experiments
The signal phase obtained from a SAW biosensor is related to the
mass changes caused by the investigated molecules. A prediction of
whether a molecule is able to cause a sufficient mass change to obtain a
detectable signal is useful to estimate the feasibility of the approach.
The following formula is applied to estimate the feasibility of the
method. This formula determines the maximum amount of analyte that
can be detected, with the assumption that all binding sites of the im-
mobilized pAb are available and active, calculated as follows. A
quantitative standard for sensitivity is the equipment specific detection
limit of 0.5 pg/mm2 [32], indicated as follows:
= × ×× >X P MW fS MW 0.5 pgmmA L 2
where, X: the theoretical area-concentration of bound analyte (in pg/
mm2); P: the phase shift (°) related to surface immobilized pAb; MWA is
the molecular weight of the analyte (in 136 320 pg/pmol); MWL is the
molecular weight of the pAb (in 150 000 pg/pmol); S: the conversion
factor and is equipment specific (i.e. 0.0515°mm2/pg); f: binding stoi-
chiometry, in the case of pAb, f was taken 2.
2.3.3. Relative response
The different immobilization techniques were compared using
normalized response values, calculated as follows:
= ×RR 100% analyte max
where, RR%= the relative response (%); analyte =phase shift (°) of
analyte injection at 350s (the equilibrium state at association phase)
and max =maximum phase shift upon E. coli L-ASNase binding (°) i.e.
phase shift if all immobilized pAb are occupied, calculated with the
formula = × SXmax , where X is the theoretical area-concentration of
bound analyte (in pg/mm2) and S: the conversion factor and is equip-
ment specific (i.e. 0.0515°mm2/pg).
2.3.4. Percentage non-specific binding
Non-specific binding was expressed as the ratio of the BSA response
to the L-ASNase response:
= ×NSB 100% BSA analyte
where, NSB%= the relative amount of non-specific binding (%); BSA
=phase shift of 100 nM BSA injection at 350s (°) and analyte =phase
shift of 100 nM L-ASNase injection at 350s (°).
2.3.5. Binding behavior
The binding behaviour was studied using 0, 10, 25, 50, 100, 150,
200, 250, 300, 350 and 400 nME. coli L-ASNase in HBS (20mM HEPES,
150mM NaCl, pH 7).
2.4. Final method
Prior to the assay experiment, a carboxymethylated dextran hy-
drogel chip was prepared according to the proced. in Section 2.2. The
pAb was immobilized on the chip as following: 50 μg/ml protein G (in
10mM sodium acetate buffer pH 4.5) was covalently immobilized to
the surface using amine coupling by performing three 130 μl injections.
Further on, three successive 140 μL of 25 μg/ml antibody was injected
in acetate buffer, pH 4.5. Then, the 10 μL of 1mM of the BS3 was in-
jected by 30 μL/min. Finally, 100mM Gly-HCl solution (pH 2.7) was
injected.
The assay experiment was performed at 30 μl/min over the SAW
chip using HBS (20mM HEPES, 150mM NaCl, pH 7.4) as running
buffer. 200 μl of reference solution or sample solution was injected
(400 s duration), followed by a 10min dissociation phase, during which
only HBS buffer was passed over the surface. After the dissociation,
regeneration was carried out with 30 μl regeneration solution consisting
of 25mM NaOH and 0.05% SDS, followed by two 30 μl HBS buffer
injections to prevent carry-over. In addition, a blank injection (HBS
running buffer) was performed prior to each binding experiments and
its response was subtracted from the response of the analyte injections.
5, 8, 10, 12 and 15 nM L-ASNase solutions in HBS buffer (20mM HEPES,
150mM NaCl, pH 7.4) were injected as the reference solutions for the
fitting of calibration curve. 10 nM sample solution (i.e. 0.136 μg/ml L-
ASNase as commercially available) in HBS buffer was injected for the
assay, corresponding to the theoretical 100% label claim (l.c.). The
response (y) is the phase (°) at 350 s, i.e. at the equilibrium steady state
of association stage.
2.5. Method validation
For the selectivity test, E. coli L-ASNase was compared with Erwinia
chrysanthemi L-ASNase (ERWINASE®), injecting 50 and 200 nM of each.
For the validation of the calibration curve, 5, 8, 10, 12 and 15 nM L-
ASNase solution was injected as the reference solutions (n=15). The
response (y) is the phase (°) at 350 s, i.e. at the equilibrium steady state
of association stage. The recovery is calculated as the ratio between the
concentration found and the theoretical concentration.
3. Results and discussion
3.1. Method development
3.1.1. Selection of immobilization method
Different immobilization proced.s have been described for proteins
and antibodies, which can be classified in two main groups: random
immobilization (i.e. amine coupling, sulfhydryl coupling, hydrazide
-activated carbonyl coupling, and EDC-mediated carboxyl coupling)
and site-directed immobilization (i.e. protein G coupling, and BS3 ac-
tivated amide coupling via protein G) [33]. Since the immobilization
does not always result in active pAb, the binding sites can be inactive or
inaccessible, the choice of immobilization strategies play a significant
role for the signal magnitude [34]. Therefore, four responses have been
applied to select the most suitable immobilization method: surface
immobilized pAb density, absolute response, normalized response and
percentage non-specific binding (Fig. 1). First, the surface immobilized
pAb density was investigated: the concentration of total bound L-AS-
Nase of each immobilization strategy exceeded the theoretical limit of
detection of 0.5 pg/mm2 (Fig. 1A), indicating a detectable E. coli L-
ASNase signal by each immobilization strategy [32]. The immobiliza-
tion of L-ASNase using amine coupling resulted in the highest active
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Fig. 1. Quantitative evaluation of immobilization strategies. A. Surface immobilized pAb density (pg/mm2). B. Absolute response of L-ASNase (phase, °). C.
Normalized response values (RR %). D. Percentage non-specific binding (NSB %). Mean values are represented, with the error bars representing the standard
deviation (amine n= 4; aldehyde n=2; EDC-mediated n=4; thiol n= 5; protein G n=5; BS3-protein G n=5).
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pAb surface (187.7 ± 27.5 pg/mm2, Supplementary Information 3),
while the density of immobilized pAb by EDC-mediated coupling is the
lowest (17.0 ± 1.1 pg/mm2). Secondly, the absolute response being
the phase value after the injection of L-ASNase showed the highest value
for the aldehyde immobilization (Fig. 1B). Moreover, the relative re-
sponse RR% is a normalised value of the determined phase (at 350 s) of
E. coli L-ASNase solution relative to the theoretical maximum phase
shift (at 350 s) upon E. coli L-ASNase binding (see Section 2.3.3). RR%
was applied to compare the binding capability (i.e. the remaining ac-
tivity of the pAb binding sites on the chip surface) between different
immobilization methods. The random orientation of the pAb often re-
sults in loss of the binding capability of analyte, with for the amine
coupling a RR% value of 3.1 ± 0.1% was obtained (Fig. 1C) [35]. The
RR% for the protein G coupling immobilization is quite low (RR
%=2.0 ± 0.1%), which can also be due to dissociation of the pAb-
protein G complex after immobilization. Finally, the selectivity was
quantitatively expressed as NSB% using a negative control BSA. The
NSB% expresses the ratio of the signal of a “random” protein (e.g. BSA)
related to an analyte signal. The “random” protein is associated with
the dextran layer and gold via non-selective interactions. The NSB% is
preferably as low as possible. The linker BS3 fixes the pAb on the pro-
tein G, therefore this immobilization is expected to have the highest
selectivity, which was confirmed by its low NSB% (0.9 ± 0.3%,
Fig. 1D). Overall, BS3 activated amide coupling via protein G had a
relatively high RR% and a low NSB%; therefore, this approach was
taken as the final immobilization method.
3.1.2. Binding behaviour
According to the binding model = = KL ALA kk d[ ][ ][ ] offon , the complex [LA]
can be calculated as = +LA[ ] L AK A[ ][ ][ ]Td (Equation 1), which is a rationalfunction. [L], [A] and [LA] represent the concentrations of “free” ligand
and analyte, and the concentration of complex respectively. The kon, koff
and Kd are respectively the on-rate constant, off-rate constant and
equilibrium dissociation constant, where the total concentration [LT]
equals to [L]+[LA] [36]. When the free concentration of analyte [A] is
low, Equation 1 equals to =LA A[ ] [ ]LK[ ]Td with a slope of LK[ ]Td . With in-creasing [A] concentration, the binding active sites of the immobilized
ligand will become fully occupied with the analytes, and the association
state gets to equilibrium state ( =LA L[ ] [ ]T ). The rate of uptake of the
analytes equals to the rate of release of the analyte from the complex,
which is observed after 350 s (Fig. 2A). The response (phase in °) at
350 s (equilibrium state) increases steeply in the concentration range of
0–25 nM of L-ASNase, with plateauing beyond 50 nM (Fig. 2B). The
binding active sites on the surface are then fully occupied and the slight
steady increase in phase is thus caused by mass transport limitation
[37,38]. This binding behavior was important for the calibration curve
in the assay, which was thus focused in the 5–15mM range.
3.2. Method validation
The sensorgram of E. coli L-ASNase showed a kinetic association,
followed by a dissociation step, while Erwinia L-ASNase showed no in-
teraction (Fig. 3), indicating that the developed SAW biosensor method
is selective for the E. coli L-ASNase.
The calibration curve for the functional quantification of L-ASNase
was investigated using the concentration range of 5–15 nM, e.g. 5, 8, 10
(i.e. 100% l.c.), 12 and 15 nM. A quadratic model was found to be the
best fit for the quantification of E. coli L-ASNase, yielding the equation
y=−0.0008x2+0.0249x-0.0091, with an ANOVA F value of 242 and
R2 of 0.9959 (Fig. 4). The 95% confidence interval (95% CI) of the
coefficients were 0.0014 to −0.0003 for −0.0008, 0.0138 to 0.036 for
0.0249, and −0.061 to 0.0428 for −0.0091 (hence, including the
zero). The recovery is calculated as the ratio between the concentration
found and the theoretical concentration. The precision is calculated as
the relative standard deviation (RSD%) of the equilibrium phase of each
meas. ments. The recovery is 102.4%, with the precision of 8.5% for
10 nM (n= 15).
3.3. Application
The applicability of the developed and validated method was de-
monstrated by analyzing several L-ASNase samples: a commercial batch
of E. coli L-ASNase, another E. coli L-ASNase batch from the same sup-
plier, a stress-degraded dry-heated (80 °C, 10min) E. coli L-ASNase and
a deamidated E. coli L-ASNase. The results obtained were 101.0% l.c.
(RSD of 6.5%) and 100.7% l.c. (RSD of 13.7%) for both batches of E. coli
L-ASNase of the same supplier, confirming the quality consistence as
expected from pharmaceutical GMP. The stress-degraded sample, ob-
tained by a short period of dry heating, showed a reduced assay value of
93.8% l.c. (RSD of 5.7%). The deamidated E. coli L-ASNase showed an
assay value of 90.3% l.c. (RSD of 8.3%), also well below the generally
accepted specification limit of 95% l.c.
4. Conclusion
A SAW method for the functional quantification of E. coli L-ASNase
was developed. Several immobilization strategies were first quantita-
tively evaluated by the immobilized pAb density, absolute response,
normalized response and non-specific binding, leading to the BS3 acti-
vated amide coupling via protein G strategy as final immobilization
method. After the binding behavior was characterized, a final method
was proposed, which was validated. Finally, this validated method was
Fig. 2. A: SAW sensorgrams of L-ASNase and pAb interaction (L-ASNase concentration of 0–400 nM). B: Phase (°) responses at 350 s (equilibrium state) with different
L-ASNase concentrations in the range of 0–400 nM.
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applied on different E. coli L-ASNase samples. This developed SAW
method can thus be adopted as a pharmaceutical quality control
method for L-ASNase medicines and proves the usefulness of biosensors
in QC of biologics.
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